Caverta is an India-market sildenafil tablet brand explicitly included in Sun Pharmaceutical Industries’ corporate India product catalog. Sun Pharma identifies three Caverta tablet listings—25 mg, 50 mg and 100 mg—and states sildenafil as the active ingredient for each. Those documented presentations provide a substantially stronger basis for a brand-specific page than a generic list of precautions.
In the company’s India portfolio, Caverta appears as a tablet line, distinct from Sun Pharma’s tadalafil product names Forzest and Modula. Some Indian pharmacy catalogs also identify Caverta 50 as sildenafil 50 mg and name Sun Pharmaceutical Industries as marketer. Product name, ingredient and company association are supported; that does not independently confirm individual pack authenticity or imply a U.S. marketing authorization.
This article explains the concrete Caverta lineup, how it compares with other Sun Pharma products, and how an India-market catalog differs from FDA-approved U.S. sildenafil. It does not include price quotes or import offers. Browse Indian sildenafil brands or the U.S. generic product guide for the separate topics.
Sun Pharmaceutical Industries publishes a structured India product list in which Caverta appears with exact strength, molecule and tablet designation. The rows below reflect those company records rather than an inferred product range taken from reseller search results. They demonstrate that three named sildenafil tablet strengths are part of the listed Indian portfolio.
A listed branded tablet is still not the same as an authenticated package received from a particular dispenser. The record supports brand identity at the catalog level and keeps real-time availability, company site and regulatory license as separate questions.
| Listed Sun Pharma product | Ingredient / form | What the listing establishes |
|---|---|---|
| CAVERTA 25 MG TABLET | Sildenafil 25 mg, oral tablet | Listed in Sun Pharma’s India products |
| CAVERTA 50 MG TABLET | Sildenafil 50 mg, oral tablet | Listed in Sun Pharma’s India products; Indian pharmacy record also exists |
| CAVERTA 100 MG TABLET | Sildenafil 100 mg, oral tablet | Listed in Sun Pharma’s India products |
| FORZEST 20 MG TABLET | Tadalafil 20 mg, oral tablet | Same company, different ingredient and brand; not Caverta |
| MODULA 5 MG TABLET | Tadalafil 5 mg, oral tablet | Separate tadalafil product, not a Caverta strength |
A company-authored portfolio is useful because it directly associates Sun Pharmaceutical Industries with the Caverta entries. It identifies the category as sildenafil tablets and differentiates the 25/50/100 strengths in a consistent format. This is more specific than an anonymous reseller claim that a product is “made in India.”
The list does not function as a batch authenticity certificate, does not identify every possible distribution arrangement and does not establish current legal status for a given jurisdiction. Exact manufacturer and marketer information on a physical carton must be interpreted according to what that individual pack actually says.
A major Indian pharmacy catalog separately identifies Caverta 50 Tablet as sildenafil 50 mg and names Sun Pharmaceutical Industries Limited as marketer. That gives some consistency between a corporate listing and a retailer’s product identity. The same retailer may display dynamic stock, pack quantities or offers, none of which belong in an evergreen reference page.
This cross-check supports the specificity of the Caverta 50 entry, but it does not establish that an unrelated international website is legitimate or that a visually similar product is authentic. Identifying the exact formulation and who dispensed it remains essential.
A distinctive source of confusion is that Sun Pharma’s India catalog lists Caverta near other sexual-health medicines. Forzest 20 and Modula 5 appear in that portfolio as tadalafil products, not Caverta tablets. Because both ingredients belong to the broader PDE5 inhibitor class, broad marketing pages sometimes group them together as if they were versions of one drug.
That would be inaccurate: sildenafil and tadalafil are different medicines with different labeling and dosing schedules. Readers researching the ingredient difference should use sildenafil versus tadalafil and not infer substitution from the fact that one company markets both.
Caverta’s India-market 25, 50 and 100 mg listings happen to match the strengths on U.S. Viagra ED tablets. This is a numeric overlap, not confirmation of an FDA-approved Caverta application or approved therapeutic-equivalence rating. Ingredients, product authorization, approved labeling and quality-assurance evidence need product-specific evaluation.
For the U.S. reference, Viagra is the original brand context and generic sildenafil covers approved alternatives. This page remains a study of Caverta’s India-market identity, rather than a brand-versus-generic purchasing comparison.
The corporate product list gives names, strengths and dosage forms. A detailed record of a particular pack may also include batch number, manufacturing site, expiry date and legal marketer. Those additional fields should not be invented from the brand family. A product listing that mentions “Caverta” but no strength does not identify which of the three company-listed presentations is meant.
If a seller claims a Caverta gel, combined formulation or higher strength, such a product needs separate documentary evidence. It should not automatically be added to the established three-item tablet lineup.
Caverta’s listed active ingredient is sildenafil, whose relevant clinical cautions include dangerous interactions with organic nitrates and riociguat. Cardiovascular history, other prescribed drugs and potential adverse reactions need attention before use. Even an accurately described product is not evidence that it is appropriate for a particular individual.
A prolonged erection lasting more than four hours requires emergency care; sudden vision or hearing changes require prompt evaluation. Ingredient guidance is available at sildenafil side effects and sildenafil and nitrates.
Sun Pharma’s India product catalog is strong evidence for what the company lists in India, but it does not grant Caverta an FDA-approved U.S. product identity. U.S. generic approval is assessed under separately approved product applications. It is misleading to describe the Indian brand as U.S. approved simply because sildenafil generics exist in both markets.
For FDA-approved domestic alternatives and actual pharmacy verification, review U.S. prescription sildenafil and licensed online pharmacy checks. Unapproved prescription-drug importation is generally prohibited.
Prices and inventory shown on Indian retail pages are variable and depend on location, pack, payment method and seller terms. They are not appropriate proxies for what an FDA-approved U.S. sildenafil prescription will cost. Publishing copied currency amounts or claiming Caverta is always cheaper would produce stale and misleading advice.
The durable U.S. approach is to ask a licensed pharmacy for the complete amount associated with the exact prescribed product, quantity and payment method. Sildenafil cost factors explains this without importing foreign-market retailer data.
Caverta’s strongest distinctive evidence is a Sun Pharma corporate catalog listing three single-ingredient strengths. Suhagra is separately documented by Cipla and has a named combination extension, Suhagra Force. Manforce is linked to Mankind Pharma, which uses similar brand naming across different drug compositions.
These company-level distinctions should guide brand research; unsupported rankings of which India-market brand is “stronger” should not. A U.S. prescription selection remains a clinical and FDA-product question.
Caverta is an India-market sildenafil tablet brand listed in Sun Pharmaceutical Industries’ corporate India product catalog.
Its India products list includes Caverta 25 mg, 50 mg and 100 mg tablets, all identifying sildenafil.
Yes. An Indian pharmacy catalog identifies Caverta 50 as sildenafil 50 mg and names Sun Pharmaceutical Industries as marketer.
No. Caverta is listed as sildenafil; Forzest is a separately named tadalafil product.
No. Identical strength numbers are not proof of FDA product approval or therapeutic equivalence.
The documented Sun Pharma lineup discussed here includes three conventional tablet strengths; other claims need independent product-specific evidence.
No. An Indian product listing cannot establish U.S. dispensing authorization or pharmacy stock.
Discuss an appropriate FDA-approved ED medicine with a clinician and use a licensed U.S. pharmacy for any valid prescription.